Prediction of response to Certolizumab-Pegol in rheumatoid arthritis (PreCePRA) by functional MRI of the brain – Study protocol for a randomized double-blind controlled study

BACKGROUND: Tumor necrosis factor inhibitors (TNFi) signify a major advance in the treatment of rheumatoid arthritis (RA). However, treatment success initially remains uncertain as approximately half of the patients do not respond adequately to TNFi. Thus, an unmet need exists to better predict ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Schenker, H.M., Tascilar, K., Konerth, L., Sergeeva, M., Prade, J., Strobelt, S., Kleyer, A., Simon, D., Mendez, L., Hagen, M., Schönau, V., Hueber, A., Roesch, J., Dörfler, A., Hess, A., Schett, G., Rech, J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8144682/
https://www.ncbi.nlm.nih.gov/pubmed/34041413
http://dx.doi.org/10.1016/j.conctc.2021.100770

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8144682/
https://www.ncbi.nlm.nih.gov/pubmed/34041413
http://dx.doi.org/10.1016/j.conctc.2021.100770

Ejemplares similares